Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
GeoVax (GOVX) Reports 2025 Year-End Financial Results and Provides Business Update
LIVE QUOTE
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)
Scheduled to Initiate During the Second Half of This Year
ATLANTA, GA - April 15, 2026 (NEWMEDIAWIRE)...
Report: AI Powered Review on GeoVax (GOVX) $1.15
In our view, a research report is designed to gather information on publicly traded companies from press releases, management presentations (including power points), SEC...
Biotech Stock Review is Back! Timing Feels Perfect. 4 Companies Added to Watch List.
Biotech 12 Pack Watch List to be Released.
In 2020, we Released the "Biotech 5 Pack" Which Later Grew to a 6 Pack, with a...
Latest article
Cabaletta (CABA) Surges 44% on Massive Volume Spike.
Biotech 12 Pack Off to Nice Start..
Cabaletta up 35%, GeoVax up 75%, and Replimune up 62%. All since late April!
Biotech Stock Review is...
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Wednesday afternoon, the 29th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
